Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Deltarasin + Infigratinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Deltarasin||Deltarasin is an inhibitor of the interaction between Kras and the prenyl-binding protein PDEdelta, resulting in decreased KRAS signaling, and potentially leading to reduced tumor cell proliferation and inhibition of tumor growth (PMID: 23698361).|
|Infigratinib||Truseltiq||BGJ398|BGJ-398|BGJ 398||FGFR Inhibitor (Pan) 19||Truseltiq (infigratinib) is a pan-FGFR inhibitor, which inhibits tumor angiogenesis and tumor cell proliferation (PMID: 31109923, PMID: 30101387). Truseltiq (infigratinib) is FDA approved for use in patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusion or rearrangement (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|